Schering-Plough France, Preclinical Development Center, 20 rue Henri Goudier, B.P. 140, 63203 Riom Cedex, France
Abstract:
Compound 1 is a low molecular weight thrombin inhibitor developed for treatment of deep vein thrombosis and cardiovascular diseases. We herein report our efforts to develop a robust, efficient and reproducible process suitable for large-scale synthesis of compound 1.